Edap Tms Sa Liquidation Value

EDAP Medical Devices

Cash & Equivalents

$15.01M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $15.01M
Total Obligations: -$57.46M
$-42.45M
Per share: $-1.13
Period: 2026-03-31

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $15.01M
AR: $19.65M
Total Obligations: -$57.46M
$-22.79M
Per share: $-0.61
Period: 2026-03-31

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $15.01M
AR: $19.65M
Inventory: $13.33M
Total Obligations: -$57.46M
$-9.46M
Per share: $-0.25
Period: 2026-03-31

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-42.45M$-1.13
Liquid Liquidation Value$-22.79M$-0.61
Operating Liquidation Value$-9.46M$-0.25

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-05-07. View on SEC EDGAR →

Cash & Equivalents$15.01M
Accounts Receivable$19.65M
Inventory$13.33M
Current Liabilities$37.51M
Long-term Debt (?)$17.60M
Op. Lease Liability (?)$1.91M
Finance Lease (?)$436,000
Shares Outstanding37.5M

Explore all 115 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$15.01M$19.65M$13.33MN/A$37.51M$17.60M$1.91M$436,000
2025-12-31$20.45M$21.29M$12.83MN/A$37.14M$15.90M$2.08M$355,000
2025-03-31$24.69MN/A$81,000N/AN/AN/AN/AN/A
2024-12-31$31.00M$19.32M$19.21MN/A$39.28M$2.25M$1.65M$364,000
2023-12-31$48.03MN/AN/AN/AN/AN/AN/AN/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-05-07 View
2025-12-31 10-K 2026-03-25 View

AI Insights

AI Insight·Generated 2026-05-09

EDAP TMS SA (EDAP) presents a negative liquidation recovery posture as of March 31, 2026. Total assets of $72.1M against total liabilities of $62.0M yields book equity of $10.1M, but liquidation haircuts eliminate this cushion and generate a meaningful deficit to equity. Applying standard recovery rates: cash of $15.0M recovers at 100% ($15.0M); net accounts receivable of $19.7M current plus $1.0M noncurrent recovers at 90-95% (~$18.7M); inventory net of $13.3M recovers at 60% ($8.0M); PP&E and finance lease ROU of $10.2M recovers at 50-70% (~$5.1-7.1M); operating lease ROU of $2.8M recovers at 0% under liquidation (obligation survives); intangibles net of $1.7M and goodwill of $2.8M recover at 0%; deferred tax assets of $1.1M recover at 0%; other current assets of $1.7M recover at 50% (~$0.9M). Estimated gross liquidation asset pool: approximately $48-50M. Against this, total liabilities of $62.0M stand at face value, inclusive of long-term debt of $17.6M noncurrent and $1.5M current (EIB Finance Contract, Tranche A drawn), short-term borrowings of $5.2M, deferred revenue current $7.8M and noncurrent $1.1M (service obligations do not extinguish on windup), operating lease liabilities $0.9M current and $1.9M noncurrent, finance lease liabilities $0.7M combined, pension obligation $2.3M (defined benefit plan, survives windup), accrued payroll taxes $2.2M, and other current liabilities $5.7M. The shortfall to equity under liquidation is approximately $12-14M, consistent with the MFFAIS CLV of negative $42.4M at the most conservative cut and OLV of negative $9.5M at the most optimistic. A material subsequent event—the April 1, 2026 draw of Tranche B from EIB of EUR 12.0M (approximately $13.3M at prevailing rates), disbursed April 20, 2026—adds approximately $13-14M of additional senior secured debt to the liability stack post-period, further widening the liquidation deficit. The filing discusses the Tranche B EIB borrowing extensively in MD&A and Note 19 but the debt instrument amount is tagged only via a custom XBRL tag (edap:DebtInstrumentAmountRequestedForDisbursement) not included in TAG_CONTEXT; accordingly it is noted here rather than in tag_insights. Cash burned $5.4M in Q1 2026 (operating outflow $3.0M, investing $0.8M, financing $1.4M, FX $0.3M), reducing the single most liquid asset from $20.5M to $15.0M QoQ. Management acknowledges going concern uncertainty in the liquidity section if Tranche B and other financing measures are insufficient. The EIB warrant fair value change ($1.3M in Q1 2026 vs. immaterial in Q1 2025) introduces a recurring non-cash charge that inflates net loss relative to operating cash burn but does not affect liquidation liability quantum directly. G&A jumped 58.5% YoY driven by domestic filer transition costs, accelerating the operating cash consumption rate.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...